Table 2.
Steroid medications in platelet and granulocyte donors.
Route of administration | Exposure level* | Platelet donors (n=100) | Granulocyte donors (n=100) | p-value† |
---|---|---|---|---|
Skin | None | 83% | 79% | 0.69 |
Moderate | 12% | 16% | ||
High | 5% | 5% | ||
Inhaled | None | 92% | 91% | 1.00 |
Moderate | 7% | 7% | ||
High | 1% | 2% | ||
Oral | None | 99% | 100% | 1.00 |
Moderate | 1% | 0% | ||
Injected | None | 100% | 100% | . |
Nasal | None | 77% | 75% | 0.68 |
Moderate | 16% | 20% | ||
High | 7% | 5% | ||
Ocular | None | 97% | 94% | 0.50 |
Yes | 3% | 6% | ||
Overall exposure to steroids | None | 61% | 54% | 0.62 |
Moderate | 24% | 29% | ||
High | 15% | 17% |
Derivation of risk level from steroid medication history. For skin, inhaled, oral, injected, and nasal, the risk level was based on the approximate total duration of steroid medication use.
Exact likelihood ratio chi-squared test